DRUG GMP WARNING LETTERS FOR FY 2006
This article was originally published in The Gold Sheet
Executive Summary
...give evidence to FDA’s current concern with data integrity. The agency’s findings are spurring further investigations and public warnings to companies to pay attention to their operations. A planned field office reorganization and cutbacks could impact FDA enforcement activity and challenge the boundaries of risk management. [A dicussion by a field compliance official of FDA’s current concerns with data integrity and steps to avoid problems is included. The drug GMP warning letters issued in FY 2006, nearly as low in number as in FY 2005, are listed. The listing is organized according to the type of facility involved, and includes the recipient’s name, letter date, plant location and a description of the problem areas cited.]
You may also be interested in...
Hussain: Empowering Workers is the Key to Data Integrity
Why would pharmaceutical quality personnel fib about something like a batch test? Ajaz Hussain, the former FDA’er who helped launch the 21st Century Quality Paradigm, may have found the answer in the science of human behavioral economics.
Data Integrity Problems Continued to Surface in Recent Warning Letters
Recent GMP warning letters featured data integrity issues.
Data Integrity Problems Continued to Surface in Recent Warning Letters
Recent GMP warning letters featured data integrity issues.